Does limited virucidal activity of biocides include duck hepatitis B virucidal action? by Sauerbrei, Andreas et al.
RESEARCH ARTICLE Open Access
Does limited virucidal activity of biocides include





1, Holger F Rabenau
2,3 and Peter Wutzler
1,3
Abstract
Background: There is agreement that the infectivity assay with the duck hepatitis B virus (DHBV) is a suitable
surrogate test to validate disinfectants for hepatitis B virucidal activity. However, since this test is not widely used,
information is necessary whether disinfectants with limited virucidal activity also inactivate DHBV. In general,
disinfectants with limited virucidal activity are used for skin and sensitive surfaces while agents with full activity are
more aggressive. The present study compares the activity of five different biocides against DHBV and the classical
test virus for limited virucidal activity, the vaccinia virus strain Lister Elstree (VACV) or the modified vaccinia Ankara
strain (MVA).
Methods: Virucidal assay was performed as suspension test according to the German DVV/RKI guideline. Duck
hepatitis B virus obtained from congenitally infected Peking ducks was propagated in primary duck embryonic
hepatocytes and was detected by indirect immunofluorescent antigen staining.
Results: The DHBV was inactivated by the use of 40% ethanol within 1-min and 30% isopropanol within 2-min
exposure. In comparison, 40% ethanol within 2-min and 40% isopropanol within 1-min exposure were effective
against VACV/MVA. These alcohols only have limited virucidal activity, while the following agents have full activity.
0.01% peracetic acid inactivated DHBV within 2 min and a concentration of 0.005% had virucidal efficacy against
VACV/MVA within 1 min. After 2-min exposure, 0.05% glutardialdehyde showed a comparable activity against DHBV
and VACV/MVA. This is also the case for 0.7% formaldehyde after a contact time of 30 min.
Conclusions: Duck hepatitis B virus is at least as sensitive to limited virucidal activity as VACV/MVA. Peracetic acid is
less effective against DHBV, while the alcohols are less effective against VACV/MVA. It can be expected that in
absence of more direct tests the results may be extrapolated to HBV.
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Background
Hepatitis B is one of the major public health problems
worldwide since approximately 350 million, i.e. 5% of
the total population, are infected chronically [1]. An
important way to prevent infections encompasses dis-
infection measures to interrupt transmission by the in-
activation of the virus on instruments, surfaces and in
biological materials [2]. The hepatitis B virus (HBV) can
be inactivated effectively inter alia by chemical biocides
characterized by broad-spectrum virucidal activity accord-
ing to the norm EN 14476:2007 [3]. However, the num-
ber of agents achieving broad-spectrum virucidal efficacy
is limited and they are not required for the inactivation
of HBV such as other human blood-borne viruses since
these lipophilic viruses with an envelope are character-
ized by lower stability than viruses without envelope [4].
Thus, a German guideline for testing the virucidal activity
of chemical disinfectants in the human medical area [5]
differentiates between disinfectants with virucidal activity
effective against non-enveloped plus enveloped viruses
and disinfectants with limited virucidal activity exclu-
sively effective against enveloped viruses. Limited viruci-
dal activity has been declared when there is a proven
efficacy against two representatives of enveloped viruses,
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modified vaccinia Ankara strain (MVA) [6] and the
bovine viral diarrhea virus (BVDV) strain NADL. Even
though biocides with limited virucidal activity can be
assumed to be effective against HBV, an efficacy can-
not be predicted reliably and, therefore, the virucidal
efficacy against HBV has to be validated by the use
of robust laboratory methods.
So far, the virucidal efficacy of biocides against HBV
can be stringently determined only in vivo by chimpanzee
infection assays [7] with less sensitivity or by the use of
primary hepatocyte cultures derived from Tupaias, small-
squirrel-like animals living in Southeast Asia [8]. How-
ever, while animal protection and economic reasons
prohibit the use of higher primates for routine tests on
commercial products, the Tupaia model is expensive,
the availability of hepatocytes is limited and the test
requires human sera with high viral load. Furthermore,
surrogate assays for measuring integrity of viral DNA [9],
activity of viral DNA polymerase [10], reactivity of HBV
surface antigen [11] and the physical integrity of infec-
tious viral particles [12] do not correlate reliably with the
infectivity of HBV. In addition, the use of the hepatoma
cell line HepG2 [13] is very doubtful. However, rediffer-
entiated Hepa RG cells [14] are well accepted and repro-
ducible as HBV infectivity system, but they have not
been applied for testing the hepatitis B virucidal activity
of biocides. Thus, the most promising and feasible assay
is at present the use of a taxonomically related surrogate
virus of the same virus family Hepadnaviridae, namely,
the duck hepatitis B virus (DHBV), which can be propa-
gated in ducklings or in primary duck embryonic hepa-
tocytes [15,16]. Duck hepatitis B virus shares many
physical properties with the closely related HBV [17]
and similar inactivation kinetics by disinfectants com-
pared with chimpanzee transmission studies of HBV
have been reported [7]. In Germany, the infection of
primary duck embryonic hepatocytes with DHBV was
established and evaluated for virucidal testing in sev-
eral studies [18-20].
The objective of the present study was to compare the
limited virucidal activity of different biocides, which are
often used as ingredients in disinfectants, against DHBV
and VACV/MVA. The results should provide informa-
tion whether the virucidal activity of biocides against
VACV/MVA, the most important model viruses for the




Primary duck embryonic hepatocytes were prepared
from liver tissue as described previously [18-20]. Briefly,
fertilized Peking duck eggs obtained from the poultry farm
Pötzsch (Ostrau, Germany) were incubated at 37.8°C for
21 days. The liver tissue was harvested from 6–7
embryos under sterile conditions, pooled, minced and
washed subsequently with phosphate-buffered saline
(PBS) supplemented with 1 mg/ml glucose. To ensure
the absence of DHBV in the source tissue, the first
wash fluid containing blood and liver cells was exam-
ined for DHBV DNA by using a qualitative polymerase
chain reaction technique [18]. Thereafter, the liver tissue
was digested with stirring in the dark using a solution
comprising of one volume 0.05% trypsin plus 0.02%
ethyl diamine tetraacetate (EDTA) solution (Invitrogen,
Karlsruhe, Germany) and 4 volumes PBS plus 1 mg/ml
glucose and the resulting cell suspension was removed
every 30 min. By the addition of 5% fetal calf serum (FCS,
PAA, Pasching, Austria), digestion was inhibited and the
cells were collected by centrifugation. After re-suspension
in growth medium, cells were stored at 4°C. Digestion of
the remaining tissue was continued using fresh trypsin/
EDTA solution.
DHBV-negative cells were seeded into 24-well culture
plates (CellBIND
W, Corning, Acton, United States) with
a seeding density of about 0.8 × 10
6 cells per ml and
1 ml per well. The growth medium consisted of Williams
medium E (Invitrogen) supplemented with 1.5% Me2SO
(Sigma-Aldrich, Taufkirchen, Germany), 15 mM HEPES
(Invitrogen), 1% insulin-transferrin-selenium solution
(Invitrogen), 10 μM hydrocortisone 21-hemisuccinate
(Sigma–Aldrich), 1 mg/ml bovine serum albumin (Sigma-
Aldrich), 2 mM L-glutamine (Lonza, Verviers, Belgium),
0.1 μg/ml fungizone (Lonza), 100 U/ml penicillin (Lonza)
and 100 U/ml streptomycin (Lonza). For cultivating, cells
were incubated at 37°C in a humidified atmosphere con-
taining 5% CO2 and the growth medium was replaced
after 24 h and on day 4.
Experimental investigations on embryonated hens’ or
ducks’ eggs are, in general, regarded as borderline trials
between in vivo and in vitro systems and do not conflict
with ethical and legal aspects of animal protection [21].
Therefore, the experiments of this study are not subject
to the “Animal Research: Reporting In Vivo Experiments”
(ARRIVE) guidelines and ethical approval was not
necessary.
Viruses
DHBV-containing serum from congenitally infected
ducks was kindly provided by Prof. M. Nassal (University
Hospital Freiburg, Department of Internal Medicine II/
Molecular Biology, Freiburg, Germany). Sera contained
between 10
6.0 and 10
7.13 tissue culture infective doses 50%
(TCID50) of DHBV per ml corresponding to 10
8.77 and
10
9.90 DHBV genomic copies. After preparation of 0.5-ml
aliquots, sera were stored at −80°C.
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Following biocides were used in this study: (i) ethanol
(30%, 40%, 50%, 60%, v/v; contact time: 1 min, 2 min),
(ii) isopropanol (20%, 30%, 40%, v/v; contact time:
1 min, 2 min), (iii) peracetic acid (0.001%, 0.005%, 0.01%,
0.05%, v/v; contact time: 1 min, 2 min), (iv) glutardialde-
hyde (0.05%, 0.1%, w/w; pH 8.4; contact time: 0.5 min,
2 min, 5 min), (v) formaldehyde (0.7%, w/v; pH 7.0; con-
tact time: 5 min, 30 min, 60 min). The pH values of the
biocides were measured if necessary.
Preparation of test samples
Test samples for the proficiency panel (stock solutions)
were generated by an independent provider (kindly pro-
vided by Dr. F. von Rheinbaben, Ecolab Deutschland
GmbH, Düsseldorf, Germany). All samples were sent
out by a commercial parcel service and arrived 24 h of
dispatch.
Determination of hepatocytotoxicity
In order to determine hepatocytotoxicity, biocides were
serially diluted tenfold in growth medium up to a dilu-
tion of 10
-8. One part by volume of water of standar-
dized hardness instead of DHBV-positive serum was
mixed with one part by volume of FCS as organic load
and eight parts by volume of the biocide. Aliquots of
100 μl from each test concentration and each dilution
were then inoculated into two wells of a 24-well micro-
titer plate containing monolayer of primary embryonic
duck hepatocytes plated 4 to 5 days before. The cells
were incubated at 37°C for 7–10 days and examined as
described in the chapter “Immunofluorescent DHBV
antigen staining”. Cytotoxicity was evident when cell
monolayers were detached from the growth surface,
hepatocytes became round and lost their typical polyg-
onal morphology.
Quantitative suspension test
Tests were carried out in accordance with the DVV/RKI
guideline including minor modifications [5]. One part by
volume of DHBV-containing duck serum and one part
by volume of FCS were mixed with eight parts by vol-
ume of the biocide in a 1.25 fold pre-dilution of the con-
centration to be tested. The tests were carried out in
ambient temperatures of 20-22°C. At the end of the
chosen exposure time, the test compounds were
removed immediately from the mixture of virus and test
formulation by the use of MicroSpin
™ S-400 HR
Columns (GE Healthcare UK Limited Little Chalfont,
Buckinghamshire, UK). To this end, 125 μl of the test
mixture was added to the MicroSpin
™ column and cen-
trifuged at 737 g for 1 min. Subsequently, 120 μl of the
eluted suspension was mixed with ice-cold cell culture
medium to obtain a virus dilution of 10
-1.7 and to
prepare serial ten-fold dilutions up to 10
-7.7. Without
delay, 500 μl of each were seeded in one well of 24-well
micro-titer plates containing monolayers of primary
duck embryonic hepatocytes at day 4 of cultivation and
50 μl cell culture medium. This resulted in final viral
dilutions from 10
-2 to 10
-8. Afterwards, the cells were
incubated at 37°C for 7–10 days.
Immunofluorescent DHBV antigen staining
Indirect immunofluorescent antigen staining was
employed for detection of DHBV surface antigen as
described previously [18,19]. In short, the cells were
washed once in PBS and fixed with acetone/methanol
(1:1) at −20°C for 10 min. After air drying, cells were re-
hydrated in PBS for 5 min and incubated with polyvalent
rabbit anti-DHBs (kindly provided by Dr. D. Glebe, Insti-
tute of Medical Virology, National Reference Centre for
Hepatitis B and D, Justus Liebig University, Giessen,
Germany) antiserum diluted 1:100 for 1 h at 37°C,
washed three times whith PBS and stained with goat
anti-rabbit IgG Alexa Fluor
W 488-labeled antibody (Life
Technologies, Darmstadt, Germany) diluted 1:400 in
PBS containing 0.001% Evans blue and Tween 80.
Stained cells were analyzed using the fluorescent micro-
scope Nikon DIAPHOT-TMD (Nikon-Corporation,
Tokyo, Japan). The total number of positive cells per
well was estimated visually.
Statistical analysis
Each experiment was performed at least eight times,
maximally twelve times. From the total number of posi-
tive cells per well (maximally 40% infected cells), the
virus titers of each test and the corresponding virus con-
trol (not treated with biocide) were calculated. Titer re-
duction is presented as the difference between the
control virus titer and the virus titer after contact time
with the biocide. This difference is given as reduction
factor (RF) including its 95% confidence interval (CI). A
reduction of infectivity of ≥4 log10 steps (inactivation
≥99.99%) was regarded as evidence of sufficient virucidal
activity. The calculation was performed most widely
according to the DVV/RKI guidelines [5].
Results
The detailed results of virucidal testing of the five differ-
ent biocide ingredients against DHBV are summarized in
Tables 1 and 2. For comparison, these tables contain the
results of testing these biocides against VACV and MVA
published previously by Rabenau et al. [6]. After expos-
ure of DHBV to 40%, 50% and 60% ethanol, ≥4 log10
reductions in viral titers were achieved after time inter-
vals of 1 min and 2 min. By contrast, the use of 30%
ethanol was associated with RFs of 2.99 ±0.78 after
1-min and 3.46 ±0.64 after 2-min exposure. These
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Ethanol 30 1 2.99± 0.78 −0.10±0.29/0.01±0.26
2 3.46± 0.64 0.32±0.28/-0.01± 0.30
40 1 ≥4.35 ≥3.28/2.94±0.27
2 ≥4.38 ≥4.59/≥4.05
50 1 ≥4.84 ≥5.11/≥4.76
2 ≥4.88 ≥5.11/≥5.76
60 1 ≥4.88 ≥5.11/≥5.76
2 ≥4.88 ≥5.11/≥5.76
Isopropanol 20 1 1.96± 0.66 0.01±0.29/0.08± 0.25
2 2.33± 0.61 −0.01±0.30/-0.04±0.30
30 1 3.39± 0.88 1.63±0.30/1.35± 0.22
2 4.10± 0.80 1.87±0.26/2.67± 0.27






Peracetic acid 0.001 1 1.36± 0.35 0.74±0.31/0.74± 0.27
2 1.67± 0.41 1.62±0.30/1.79± 0.30
0.005 1 2.43± 0.51 ≥4.50/≥5.66
2 3.05± 0.39 ≥4.50/≥5.66
0.01 1 3.55± 0.60 ≥4.48/≥4.85
2 ≥4.08 ≥4.48/≥4.85
0.05 1 ≥4.08 ≥4.15/≥4.35
2 ≥4.08 ≥4.15/≥4.35
Results for VACV and MVA are given as means calculated from the results of three different laboratories (Rabenau et al. [10]).
“≥” - Determination of RF is limited by hepatocytotoxic reactions and/or the amount. Calculation of 95% confidence interval is not possible.
1 Results are only from one laboratory.
Table 2 Limited virucidal activity of glutardialdehyde and formaldehyde against duck hepatitis B virus (DHBV)









Glutardialdehyde 0.05 0.5 2.79±0.78 1.62± 0.25/1.14±0.29
2 ≥4.05 ≥4.35/≥3.82
5 ≥4.05 ≥4.35/≥3.82
0.1 0.5 ≥4.05 2.91±0.22 / 2.21±0.25
2 ≥4.05 ≥4.35 / ≥3.82
5 ≥4.05 ≥4.35 / ≥3.82
Formaldehyde 0.7 5 2.00±0.40 1.15± 0.28/≥2.09
30 ≥3.06 >2.62/>2.14
60 ≥3.08 >3.16/>2.14
Results for VACV and MVA are given as means calculated from the results of three different laboratories (Rabenau et al. [10]).
“≥” - Determination of RF is limited by hepatocytotoxic reactions and/or the amount. Calculation of 95% confidence interval is not possible.
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VACV and MVA, but a sufficient activity was detected
for 40% ethanol within 2-min exposure. The use of 20%
isopropanol resulted in RFs for DHBV within 1.96 ±0.66
after 1 min and 2.33 ±0.61 after 2 min. Whereas 30% iso-
propanol after 1-min exposure did also not result in suf-
ficient activity (RF 3.39 ±0.88), there was sufficient
activity when 30% isopropanol was used for 2 min and
40% isopropanol for at least 1 min. In comparison, 40%
isopropanol for at least 1 min was necessary to inactivate
VACV/MVA. Peracetic acid at a concentration of 0.01%
inactivated the infectivity of DHBV after 2-min exposure
as was the case for 0.05% peracetic acid after 1 min and
2 min. No sufficient efficacy against DHBV was seen
when peracetic acid was used at concentrations of
0.001% and 0.005% after 1 min and 2 min as well as for
0.01% after 1-min exposure (RF between 1.36 ±0.35 and
3.55 ±0.60). These findings were different from those
with VACV/MVA whose infectivity was already inacti-
vated significantly by the use of 0.005% peracetic acid
after 1 min. The hepatocytotoxicity of ethanol and iso-
propanol at the concentrations tested was <2.0 log10
TCID50 of DHBV whereas the hepatocytotoxicity of pera-
cetic acid ranged between <2.0 (at concentrations of
0.001 – 0.005%) and <3.0 log10 TCID50 (at concentra-
tions of 0.01 – 0.05%).
Glutardialdehyde showed a sufficient efficacy against
DHBV corresponding to ≥4 log10 reduction in viral titers
when it was used at concentration of 0.05% for ≥2 min
and at concentration of 0.1% for ≥0.5 min. By contrast,
0.5-min exposure of 0.05% glutardialdehyde resulted in
RF of 2.79 ± 0.78. These results were in absolute con-
cordance to VACV/MVA even though ≥4 log10 titer
reduction could not always be achieved because of the
high cytotoxicity of this biocide. This also applies to
0.7% formaldehyde which did not inactivate the infect-
ivity of DHBV and VACV/MVA within 0.5-min exposure,
but resulted most likely in sufficient activity after at
least 30-min exposure. At the concentrations tested, the
hepatocytotoxicity of glutardialdehyde was <3.0 and of
formaldehyde <4.0 log10 TCID50 of DHBV.
Discussion
In principle, enveloped viruses are considered to be rela-
tively sensitive to biocides. However, validation of the
virucidal action of disinfectants against HBV is essential
since the hepatitis B virucidal activity of biocides cannot
be predicted and the human blood plasma protects the
virus from inactivation [22]. In particular, Payan et al.
[13,23] have described HBV as an enveloped virus that
may be less easy to inactivate. In Germany, a national
test method has been published for the determination of
limited virucidal activity [5] defined as active against
enveloped viruses such as HBV, human immunodeficiency
virus and hepatitis C virus (HCV) [24]. Unfortunately,
feasible HBV infectivity assays have not yet been estab-
lished for testing virucidal activity of biocides. Therefore,
surrogate infectivity assays based on DHBV have been
recommended to make a label claim of product efficacy
to hepadnaviruses by the Environmental Protection
Agency in the United States [25] and in Australia [26,27].
However, the DHBV model has also several disadvan-
tages that prevent its use in virological laboratories. The
model established in Germany [18] requires hepatocytes
from DHBV-negative duck embryos for in vitro infection.
By contrast, the virus has to be obtained from serum
of ducks infected congenitally or experimentally. This
is an unreliable source and no reasonable basis for
standardization. Furthermore, the DHBV as all hepadna-
viruses is non-cytopathogenic and additional methods
such as the indirect immunofluorescent antigen staining
are required to verify replication of DHBV in inoculated
hepatocytes. That is why information is necessary if test-
ing of biocides against DHBV is essential and should be
included in several guidelines or whether disinfectants
with the label claim limited virucidal activity according
to the German DVV/RKI guideline can be regarded as
effective against DHBV.
The present study compared the limited virucidal
activity of five different biocides, which are often used
as ingredients for commercially available disinfectants,
against DHBV and VACV/MVA. The latter represent
the classical test virus for the determination of limited
virucidal activity. The data for VACV/MVA have been
published recently to replace VACV by MVA because
of the potential risk of laboratory-acquired infections
caused by VACV [6]. To ensure the comparability of all
data, the test samples used in both studies were gener-
ated by the same provider and the quantitative suspen-
sion tests were carried out most widely in accordance
with the DVV/RKI guideline [5]. The concentrations of
the biocides and the exposure times were chosen to see
a kinetic of virus inactivation and a shift from non-
effective to effective concentrations and exposure times.
All tests were performed with a protein load of 10%
FCS. Sufficient activity was shown by a virus titer re-
duction of at least 4 log10 with the exception of formal-
dehyde that resulted in highest cytotoxicity. In most
studies reported in the literature, a compound was con-
sidered effective against DHBV when it reduced the
viral titer by at 3 log10 units [26,28]. As the results of
this study show, all basic biocides such as alcohols,
peracetic acid, glutardialdehyde and formaldehyde inac-
tivated DHBV and VACV/MVA at relatively low con-
centrations and within short exposure times. Against
ethanol and isopropanol, a marginally higher susceptibil-
ity of DHBV could be detected. By contrast, the DHBV
was more stable against peracetic acid than VACV/MVA.
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virucidal activity against both the DHBV and VACV/
MVA. Limited unpublished results with HBV and the use
of Tupaia cells correspond widely with these findings
(personal communication: D. Glebe, Institute of Medical
Virology, National Reference Centre for Hepatitis B and
D, Justus Liebig University, Giessen, Germany). Thus, the
data presented for DHBV are most likely also valid for
HBV.
In addition to VACV/MVA, the BVDV has been
recommended as second test virus for the determination
of limited virucidal activity of disinfectants according to
the German DVV/RKI guideline. Although the great
susceptibility of BVDV, the surrogate of HCV, against
biocides has not initiated extended studies, preliminary
data suggest that this enveloped virus has a comparable
if not a lower stability than VACV to biocides [29,30].
Comparable to the data presented in this study, the suit-
ability of VACV and BVDV for determining activities of
alcohol-based hand rubs against clinically relevant envel-
oped human viruses such as herpes simplex virus type 1
and type 2 as well as human and avian influenza A
viruses has been reported in the literature [31].
Conclusions
Biocides which are effective against VACV/MVA, the
most important model viruses for the determination of
limited virucidal activity, show a reliable inactivation of
DHBV infectivity. While peracetic acid is less effective
against DHBV, alcohols are less effective against VACV/
MVA. However, the findings show that DHBV and
VACV/MVA exhibit a comparable tenacity. This means
that the validation of disinfectants against DHBV can be
omitted in practice when VACV or MVA have been
included. It can be expected that in absence of more dir-
ect tests the results may be extrapolated to HBV.
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